Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mineralys Therapeutics, Inc. (MLYS)
NASDAQ:MLYS
RESEARCH TOOLSreports
Holding MLYS?
Track your performance easily
MLYS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.29 - $16.91
Previous Close$11.83
Volume512.66K
Average Volume (3M)169.72K
Market Cap
$588.76M
Enterprise Value$491.49M
Total Cash (Recent Filing)$97.27M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Mar 12, 2025EPS Estimate
-$1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.27
Shares Outstanding49,768,669
10 Day Avg. Volume106,757
30 Day Avg. Volume169,718
Standard Deviation0.17
R-Squared0.10
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)2.59
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.11
Forecast
1Y Price Target
$33.50Price Target Upside171.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Mineralys Therapeutics, Inc. News
PremiumCompany Announcements
Mineralys Therapeutics Announces Q3 2024 Results and Updates
PremiumCompany Announcements
Mineralys Therapeutics Advances Lorundrostat Trial Progress
PremiumCompany Announcements
Mineralys Therapeutics Hits Enrollment Milestone in Hypertension TrialRisk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MLYS FAQ
What was Mineralys Therapeutics, Inc.’s price range in the past 12 months?
Mineralys Therapeutics, Inc. lowest stock price was $7.29 and its highest was $16.91 in the past 12 months.
What is Mineralys Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Mineralys Therapeutics, Inc.’s upcoming earnings report date?
Mineralys Therapeutics, Inc.’s upcoming earnings report date is Mar 12, 2025 which is in 80 days.
How were Mineralys Therapeutics, Inc.’s earnings last quarter?
Mineralys Therapeutics, Inc. released its earnings results on Nov 11, 2024. The company reported -$1.13 earnings per share for the quarter, missing the consensus estimate of -$0.863 by -$0.267.
Is Mineralys Therapeutics, Inc. overvalued?
According to Wall Street analysts Mineralys Therapeutics, Inc.’s price is currently Undervalued.
Does Mineralys Therapeutics, Inc. pay dividends?
Mineralys Therapeutics, Inc. does not currently pay dividends.
What is Mineralys Therapeutics, Inc.’s EPS estimate?
Mineralys Therapeutics, Inc.’s EPS estimate is -$1.08.
How many shares outstanding does Mineralys Therapeutics, Inc. have?
Mineralys Therapeutics, Inc. has 49,768,670 shares outstanding.
What happened to Mineralys Therapeutics, Inc.’s price movement after its last earnings report?
Mineralys Therapeutics, Inc. reported an EPS of -$1.13 in its last earnings report, missing expectations of -$0.863. Following the earnings report the stock price went down -10.322%.
Which hedge fund is a major shareholder of Mineralys Therapeutics, Inc.?
Among the largest hedge funds holding Mineralys Therapeutics, Inc.’s share is RA Capital Management. It holds Mineralys Therapeutics, Inc.’s shares valued at 59M.
---
Mineralys Therapeutics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.50 (171.47% Upside)
$33.50 (171.47% Upside)
Blogger Sentiment
Bullish
MLYS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 265.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 13.8%
Last 30 Days ▼ 13.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.87%
12-Months-Change
Fundamentals
Return on Equity
-61.19%
Trailing 12-Months
Asset Growth
-3.35%
Trailing 12-Months
Company Description
Mineralys Therapeutics, Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
---
MLYS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with significant progress in clinical trials and financial stability but was offset by increased R&D expenses and a larger net loss. The company's advancement in clinical trial enrollment and diverse participant demographics are positive, but the financials indicate some challenges.Read More>---
MLYS Stock 12 Month Forecast
Average Price Target
$33.50
▲(171.47% Upside)
Technical Analysis
Crinetics Pharmaceuticals
―
Foghorn Therapeutics
―
Immunovant
―
Praxis Precision Medicines
―
Best Analysts Covering MLYS
1 Year
1 Year Success Rate
2/8 ratings generated profit
1 Year Average Return
-9.99%
reiterated a buy rating last month
Copying Mohit Bansal's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -9.99% per trade.
---